Handbook·Money in politics

What is regulatory capture?

Explainer·Verified 2026-07-10

The answer

Regulatory capture is when an agency created to oversee an industry in the public interest instead comes to serve that industry's interests, whether through direct pressure, revolving-door staffing, or slower cultural drift. Most people picture capture as an outright bribe. Economist George Stigler's 1971 paper that coined the concept argued regulation is often "acquired" by the industry it regulates for a structural reason, not a corrupt one: concentrated industry lobbying reliably outweighs diffuse public pressure, with no money changing hands illegally at all.1

How it actually works

Stigler's original model was about incentives. An industry has a small number of firms with a lot to gain from favorable rules, while the public is a large, diffuse group with little individual stake in any single regulation. That asymmetry means industry can organize and lobby far more effectively than consumers can. Later researchers, notably Daniel Carpenter and David Moss, added a second, softer mechanism: cultural or cognitive capture, where regulators absorb industry's assumptions and vocabulary simply from years of working alongside industry experts, without any bribe or illegal exchange taking place.2

The clearest recent example is the FAA's certification of the Boeing 737 MAX. A 2020 bipartisan House Transportation Committee investigation, after 18 months and access to internal documents, found the FAA had delegated large portions of certification work to Boeing employees themselves, and that FAA management had at points overruled its own engineers at Boeing's request. The report explicitly named this the result of regulatory capture.3 Two crashes tied to the certification failures killed 346 people in 2018 and 2019. The Department of Transportation's own Inspector General later confirmed gaps in FAA's oversight process.4

Financial regulation before the 2008 crisis showed a different capture mechanism: banks could choose which federal regulator supervised them, and the Financial Crisis Inquiry Commission's 2011 report found this created a race to the weakest supervisor. One Republican commissioner dissented from that framing, so treat it as a well-documented but contested finding.5 At FDA, the Prescription Drug User Fee Act has drugmakers pay fees that fund about 45 percent of the agency's budget, funding the same reviewers who evaluate those companies' drugs.6 That structure sped up review times and cleared a backlog, but researchers still debate whether it creates a soft capture risk.7

Who holds the power

Regulated industries hold an outsized information and staffing advantage. They employ the technical experts, fund some of the research regulators rely on, and hire former regulators as consultants and lobbyists, giving them a seat at the table years before and after any single decision.

Where you come in

Congressional committee reports, agency Inspector General audits, and the Financial Crisis Inquiry Commission's public hearing record are all free and searchable, and they show exactly which internal decisions and personnel moves preceded a captured outcome. The same revolving-door hiring patterns documented in the FAA and financial-regulation cases show up in ordinary agency staffing, which is why checking a regulator's post-government job history is worth doing before trusting an agency's account of its own independence.

Glossary: regulatory capture, revolving door

Sources

  1. George J. Stigler, "The Theory of Economic Regulation," 1971. source ↩

  2. Daniel Carpenter and David A. Moss (eds.), "Preventing Regulatory Capture: Special Interest Influence and How to Limit It," 2013. source ↩

  3. House Committee on Transportation and Infrastructure, "The Design, Development & Certification of the Boeing 737 MAX," 2020. source ↩

  4. U.S. Department of Transportation, Office of Inspector General, "FAA Has Completed 737 MAX Return to Service Efforts, but Opportunities Exist to Improve the Agency's Risk Assessments and Certification Processes," 2021. source ↩

  5. Financial Crisis Inquiry Commission, "The Financial Crisis Inquiry Report," 2011. source ↩

  6. U.S. Food and Drug Administration, "FDA User Fees Explained / Prescription Drug User Fee Act (PDUFA)," 2026. source ↩

  7. Cato Institute, "Evaluating PDUFA: Paying for FDA Drug-Application Reviewers by Charging User Fees," 2024. source ↩